Literature DB >> 12527475

Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors.

Tamzin L Ripley1, Christopher A Gadd, Carmen De Felipe, Stephen P Hunt, David N Stephens.   

Abstract

Mice lacking the NK1 receptor, the preferred receptor for substance P, demonstrate normal analgesic responses to morphine on the hot plate assay, but have been predicted, on the basis of conditioned place preference studies, to be insensitive to the rewarding properties of opiates. In this study, self-administration and the development and maintenance of locomotor sensitisation of both morphine and cocaine were investigated in mice that lacked the NK1 gene (NK1 knockout mice, NK1(-/-)). Both wildtype and NK1(-/-) mice learned an operant lever-press response to obtain food. When intravenous infusions of morphine (0.2 mg/kg/infusion) were substituted for the food reward, the wildtype mice initially reduced rates of lever pressing, but then increased them on the rewarded lever to obtain approx. 10 infusions per 90 min session; in contrast, NK1(-/-) mice continued to operate both the rewarded, and non-rewarded levers at low rates. Additionally, NK1(-/-) mice failed, following repeated administration, to sensitise to the locomotor stimulant effects of morphine (15 mg/kg, i.p.). These deficits were specific to opiates, since NK1(-/-) mice responding for food or cocaine self-administration (0.65 mg/kg/infusion) did not differ from wildtypes, and they showed normal behavioural sensitisation to repeated cocaine administration (10 mg/kg, i.p.). These results demonstrate that NK1 receptors are critical for the reinforcing properties of morphine, and for adaptive responses elicited by repeated opiate administration. It is postulated that substance P and the NK1 receptor may be necessary for the development of opiate, but not cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12527475     DOI: 10.1016/s0028-3908(02)00295-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  43 in total

1.  Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Vinod Kulkarni; Peg Davis; Shou-Wu Ma; Edita Navratilova; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 2.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

3.  The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking.

Authors:  Jesse R Schank; Courtney E King; Hui Sun; Kejun Cheng; Kenner C Rice; Markus Heilig; David Weinshenker; Jason P Schroeder
Journal:  Neuropsychopharmacology       Date:  2013-10-31       Impact factor: 7.853

4.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

5.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

Authors:  Takashi Yamamoto; Padma Nair; Tally M Largent-Milnes; Neil E Jacobsen; Peg Davis; Shou-Wu Ma; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2011-03-02       Impact factor: 7.446

Review 6.  Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models.

Authors:  Jennifer A Rinker; Patrick J Mulholland
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

Review 7.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

Review 8.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

9.  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Authors:  Jermaine D Jones; Taylor Speer; Sandra D Comer; Stephen Ross; John Rotrosen; Malcolm S Reid
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

10.  The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-09-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.